[go: up one dir, main page]

MX2017015817A - Anticuerpos de union a tau. - Google Patents

Anticuerpos de union a tau.

Info

Publication number
MX2017015817A
MX2017015817A MX2017015817A MX2017015817A MX2017015817A MX 2017015817 A MX2017015817 A MX 2017015817A MX 2017015817 A MX2017015817 A MX 2017015817A MX 2017015817 A MX2017015817 A MX 2017015817A MX 2017015817 A MX2017015817 A MX 2017015817A
Authority
MX
Mexico
Prior art keywords
tau
binding antibodies
binding
antibodies
relates
Prior art date
Application number
MX2017015817A
Other languages
English (en)
Inventor
Edward Ormonde Knight David
Seward Baker Terence
Anthony Griffin Robert
James MCMILLAN David
Mairet-Coello Georges
Downey Patrick
Philippe Courade Jean-
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017015817(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MX2017015817A publication Critical patent/MX2017015817A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos de unión a Tau y fragmentos de unión de los mismos.
MX2017015817A 2015-07-06 2016-07-05 Anticuerpos de union a tau. MX2017015817A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15175522 2015-07-06
PCT/EP2016/065813 WO2017005734A1 (en) 2015-07-06 2016-07-05 Tau-binding antibodies

Publications (1)

Publication Number Publication Date
MX2017015817A true MX2017015817A (es) 2018-04-10

Family

ID=53524640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015817A MX2017015817A (es) 2015-07-06 2016-07-05 Anticuerpos de union a tau.

Country Status (25)

Country Link
US (4) US10287343B2 (es)
EP (1) EP3319983B1 (es)
JP (3) JP6630426B2 (es)
KR (2) KR102770650B1 (es)
CN (1) CN107849104B (es)
AR (1) AR105267A1 (es)
AU (1) AU2016289755C1 (es)
CA (1) CA2991451A1 (es)
CL (1) CL2018000043A1 (es)
CO (1) CO2017012971A2 (es)
EA (1) EA037092B1 (es)
EC (1) ECSP18000887A (es)
IL (1) IL256685B (es)
MA (2) MA41670A1 (es)
MX (1) MX2017015817A (es)
MY (1) MY193677A (es)
PE (1) PE20180481A1 (es)
PH (1) PH12017502207B1 (es)
SG (1) SG10202010735PA (es)
TN (1) TN2017000539A1 (es)
TW (1) TWI745295B (es)
UA (1) UA124616C2 (es)
UY (1) UY36773A (es)
WO (1) WO2017005734A1 (es)
ZA (1) ZA201800027B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI827405B (zh) 2015-06-05 2023-12-21 美商建南德克公司 抗-ｔａｕ抗體及使用方法
KR102770650B1 (ko) 2015-07-06 2025-02-19 유씨비 바이오파마 에스알엘 타우 결합 항체
EP3319984A1 (en) 2015-07-06 2018-05-16 UCB Biopharma SPRL Tau-binding antibodies
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
KR102645073B1 (ko) 2016-12-07 2024-03-11 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
TWI809562B (zh) 2017-10-16 2023-07-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
EP4013772A4 (en) * 2019-08-13 2024-06-05 Washington University METHODS FOR DETECTING MTBR-TAU ISOFORMS AND THEIR USE
JP7399305B2 (ja) 2020-02-12 2023-12-15 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化
PE20230840A1 (es) 2020-06-25 2023-05-19 Merck Sharp And Dohme Llc Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
IL320461A (en) * 2022-11-14 2025-06-01 Washington University St Louis Methods for detecting MTBR-CSF Tau and its uses
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025171285A1 (en) * 2024-02-09 2025-08-14 University Of Notre Dame Du Lac Tau proteomimetics
WO2025196217A1 (en) 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP2007536898A (ja) 2003-07-01 2007-12-20 セルテック アール アンド ディ リミテッド 修飾抗体Ｆａｂフラグメント
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
HUE033438T2 (en) 2008-09-26 2017-11-28 Ucb Biopharma Sprl Biological products
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
EP2370472A4 (en) 2008-12-05 2013-04-24 Angiochem Inc LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
AU2010305284A1 (en) 2009-10-06 2012-05-03 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
JP6371526B2 (ja) 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
SG11201400125RA (en) 2011-09-19 2014-03-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
CN103946237B (zh) 2011-11-11 2017-04-12 Ucb医药有限公司 白蛋白结合抗体及其结合片段
ES2738007T3 (es) 2011-12-20 2020-01-17 Janssen Biotech Inc Anticuerpos anti-PHF-tau y sus utilizacines
SG10201913370PA (en) * 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
ES2775192T3 (es) 2012-08-16 2020-07-24 Ipierian Inc Procedimientos de tratamiento de una tauopatía
HRP20201422T1 (hr) 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
KR102770650B1 (ko) 2015-07-06 2025-02-19 유씨비 바이오파마 에스알엘 타우 결합 항체
EP3319984A1 (en) 2015-07-06 2018-05-16 UCB Biopharma SPRL Tau-binding antibodies

Also Published As

Publication number Publication date
CO2017012971A2 (es) 2018-03-09
JP7100008B2 (ja) 2022-07-12
TN2017000539A1 (en) 2019-04-12
AU2016289755A1 (en) 2018-01-04
BR112017028102A2 (en) 2018-09-04
MA41670A1 (fr) 2018-05-31
KR102770650B1 (ko) 2025-02-19
KR20180025962A (ko) 2018-03-09
CL2018000043A1 (es) 2018-05-18
US11732034B2 (en) 2023-08-22
JP2022141689A (ja) 2022-09-29
US20210115121A1 (en) 2021-04-22
UY36773A (es) 2017-01-31
US20190284267A1 (en) 2019-09-19
EA037092B1 (ru) 2021-02-04
JP7413448B2 (ja) 2024-01-15
AU2016289755C1 (en) 2021-08-19
US10889640B2 (en) 2021-01-12
US10287343B2 (en) 2019-05-14
TWI745295B (zh) 2021-11-11
CN107849104A (zh) 2018-03-27
SG10202010735PA (en) 2020-11-27
CA2991451A1 (en) 2017-01-12
JP2018524001A (ja) 2018-08-30
JP2020055849A (ja) 2020-04-09
PH12017502207A1 (en) 2018-06-11
PE20180481A1 (es) 2018-03-07
TW201713689A (zh) 2017-04-16
JP6630426B2 (ja) 2020-01-15
US20230416350A1 (en) 2023-12-28
AU2016289755B2 (en) 2020-12-03
EP3319983A1 (en) 2018-05-16
AR105267A1 (es) 2017-09-20
NZ738058A (en) 2021-07-30
EA201890172A1 (ru) 2018-10-31
US20180201666A1 (en) 2018-07-19
UA124616C2 (uk) 2021-10-20
ZA201800027B (en) 2019-06-26
WO2017005734A1 (en) 2017-01-12
IL256685B (en) 2022-02-01
CN107849104B (zh) 2021-08-27
MA42377A (fr) 2018-05-16
HK1246804A1 (zh) 2018-09-14
KR20250027278A (ko) 2025-02-25
ECSP18000887A (es) 2018-03-31
PH12017502207B1 (en) 2022-08-10
IL256685A (en) 2018-03-29
MY193677A (en) 2022-10-25
EP3319983B1 (en) 2026-01-28

Similar Documents

Publication Publication Date Title
ECSP18000844A (es) Anticuerpos de unión a tau
ECSP18000887A (es) Anticuerpos de unión a tau
IL272227A (en) Anti-tigit antibodies
IL265321B1 (en) Cd3 binding antibodies
IL269405A (en) Anti-sirp alpha antibodies
IL263840A (en) Cd3 binding antibodies
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
PL3606954T3 (pl) Przeciwciała anty-LAG3
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
DK3242892T3 (da) Modificerede april-bindende antistoffer
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3452507T3 (da) Tau-immunoterapi
EP3606963C0 (en) ANTIBODIES BINDING TO STEAP-1
EP3532034A4 (en) ANTI-APOE ANTIBODY
DK3253785T3 (da) Hidtil ukendte egfr-bindingsproteiner
DK3484921T3 (da) Anti-IL-22R antistoffer
DK3452515T3 (da) Her-2-bindende antistoffer
EP3604518A4 (en) ANTI-GPR20 ANTIBODY
EP3458484A4 (en) ANTIBODY BINDING NANOFIBRILLES
TH1601003730A (th) แอนติ-vista แอนติบอดี และชิ้นส่วนย่อย